KSKai Sun

Kai Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kai Sun has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cervical Rotation-Traction Manipulation of Different Treatment Frequency in Cervical Radiculopathy: Study Protocol for a Randomized Controlled Trial

    by Tianxiao Feng, Xu Wang, Kai Sun, He Yin, Aifeng Liu, Zhenhua Li, Jinyu Li, Liguo Zhu, Xu Wei

    Purpose: Cervical radiculopathy (CR) poses a significant challenge due to its debilitating impact. Cervical rotation-traction manipulation (CRTM) is a representative manual therapy of traditional Chinese medicine (TCM) in China, which is beneficial to improve the pain, numbness, and dysfunction of CR patients. However, the optimal treatment frequency for CRTM remains systematically underexplored in randomized controlled trials (RCTs). This clinical study aims to assess the effectiveness and safety on three sessions per week of CRTM (TSWM) compared to one session per week of CRTM (OSWM) and cervical traction (CT) in patients with CR. Patients and Methods: This multicenter, three-arm, prospective RCT is conducted at four hospitals in China. Participants will be randomly allocated in a 1:1:1 ratio to one of the TSWM group, OSWM group, or CT group through the central randomization system. All participants will receive 4-week treatment and 16-week follow-up (total 20 weeks). The primary outcome is pain intensity of neck and arm measured by the Visual Analog Scale (VAS) at week 4. The secondary outcomes include VAS for pain intensity, VAS for numbness intensity, Neck Disability Index (NDI), Short Form 12 (SF-12), the total cost, the recurrence rate, and Expectation of Treatment and Credibility Scale (ETCS). Adverse events (AEs) will be monitored and reported throughout the trial. Conclusion: We expect this clinical study to evaluate the optimal frequency of CRTM for CR. It will also serve as a reference and exploration for investigating the dose–response relationship of manual therapy. Trial Registration: This clinical trial was registered at ClinicalTrials.gov (registration number: NCT06320249) on March 15, 2024.

  • Open Access

    Targeting a Shared Mitophagy Regulator: The SIRT1–FOXO3–DEPP1 Axis Underpins the Dual Bone and Brain Benefits of Total Flavonoids from Drynaria fortunei

    by Yili Zhang, Xiangyun Guo, Qing Wang, Long Xiao, Qingqing Liu, Yiwen Gan, Yunning Li, Chuanrui Sun, Zhiwen Luo, Kai Sun, et al.

    Postmenopausal osteoporosis and depression often occur together, but a single treatment that improves both conditions is currently lacking. The loss of estrogen can trigger oxidative stress, damage mitochondria, and drive dysregulated autophagy with impaired flux, simultaneously harming bone and the brain. We evaluated whether total flavonoids from Drynaria fortunei (TFDF) could counter these problems by activating sirtuin-1 (SIRT1), a protein that supports autophagy and mitochondrial health. In menopausal and chronic stress model mice and in cultured bone-forming cells and hippocampal neurons exposed to oxidative injury, we measured bone structure and strength indicators, mood-related behaviors, mitochondrial function, and gene activity patterns. The flavonoids preserved bone density and fine bone structure, shifted bone turnover toward formation, and improved depression-like behaviors (greater exploration and sucrose preference, less immobility). Across bone and the brain, TFDF modulated SIRT1–FOXO3–DEPP1 signaling and FOXO-linked oxidative stress and autophagy programs, thereby normalizing autophagic recycling and mitochondrial function. In cellular models, TFDF preserved mitochondrial function and restored autophagic recycling, and the loss or gain of SIRT1 function abolished or enhanced these benefits, respectively, indicating that SIRT1 activity is necessary for the effects of TFDF. These findings identify TFDF as a single, mechanism-based strategy that addresses both skeletal deterioration and depressive symptoms after menopause by engaging SIRT1-dependent stress autophagy pathways to restore cellular recycling and energy control.


  • Open Access

    C-reactive protein-to-lymphocyte ratio and trabecular bone score: A mediation analysis of BMI in the NHANES 2005 to 2008 cohort

    by Zhizhuang Wang, Bo Xu, Guoliang Ma, Xin Chen, Bowen Yang, Xiaokuan Qin, Weili Duan, Minshan Feng, Kai Sun, Liguo Zhu, et al.

    Previous studies have focused on the relationship between C-reactive protein and Trabecular Bone Score (TBS), but the correlation between C-reactive protein-to-lymphocyte ratio (CLR) and TBS remains unclear. Some studies have shown that of body mass index (BMI) is associated with CLR and TBS, respectively. This study focused on the correlation between CLR and TBS and the mediating effect of BMI based on data from the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2008. This study used data from the NHANES database (1789 males and 1699 females) to perform multivariate logistic regression, population characterization, and subgroup and interaction analyses to estimate the relationship between CLR and TBS, and explored the mediating role of BMI on the correlation between CLR and TBS through mediation analysis. A total of 3488 participants aged 20 years and older were recruited for this study. Multivariate regression analysis showed that those with a high CLR had a low TBS. Mediation analyses showed that CLR had a large direct effect on TBS (P < .0001) and that BMI partially mediated this relationship (55.2148%, P < .0001). This study found that increased levels of CLR were associated with decreased TBS and were influenced by BMI. CLR may be a valuable tool for assessing bone metabolism and deserves further exploration. These findings contribute to a deeper understanding of the impact of obesity on the lineage of the relationship between inflammation and bone health and provide new perspectives on the treatment and prevention of osteoporosis and osteoporotic fractures.


  • Open Access

    Association between A body shape index and bone mineral density in middle-aged and elderly adults: a retrospective analysis of NHANES 2005–2018

    by Zhi-Zhuang Wang, Guo-Liang Ma, Bo Xu, Xin Chen, Bo-Wen Yang, Xiao-Kuan Qin, Wei-Li Duan, Min-Shan Feng, He Yin, Kai Sun, et al.

    Introduction: Despite accumulating evidence on central obesity and osteoporosis, the role of a body shape index (ABSI), a nonlinear index quantifying body shape via body mass index (BMI), waist circumference (WC), and height, remains controversial and underexplored. Although recent meta-analyses suggest central obesity may modulate fracture risk bidirectionally, no research has comprehensively compared ABSI with traditional adiposity metrics, such as BMI, WC, and waist-to-height ratio (WHtR), to predict site-specific changes in bone mineral density (BMD) across anatomical regions.Methods: This study utilized National Health and Nutrition Examination Survey (NHANES) data from 2005 to 2018, involving 12,421 participants. ABSI was computed using the formula: ABSI = WC/(BMI²/³ × Height¹/²). BMD was assessed at four sites—the total femur (TF), femoral neck (FN), trochanter (TR), and intertrochanter (IN) regions—via dual-energy X-ray absorptiometry (DXA). The association between ABSI and BMD was analyzed via multiple regression models and a generalized additive model (GAM). To compare ABSI’s predictive efficacy with conventional adiposity indices, regression analyses juxtaposed ABSI against BMI, WC, and WHtR in assessing correlations with site-specific BMD.Results: After full covariate adjustment, a significant negative association was observed between ABSI and BMD in four femoral regions (P< 0.01). Smoothed curve fitting revealed a significant nonlinear relationship and threshold effect between ABSI and BMD among middle-aged and older individuals. Additionally, an inverted J-shaped curve was observed between ABSI and BMD in all four femoral regions. Meanwhile, ABSI showed significant negative associations with BMD across all femoral sites (β = -0.27 to -0.31, p-trend< 0.000001), whereas BMI, WC, and WHtR exhibited positive correlations (WHtR showing the strongest effect: β = 0.41–0.69). This highlights ABSI’s ability to detect central adiposity-related bone loss obscured by conventional obesity metrics.Conclusion: ABSI’s robust inverse associations with femoral BMD (β = -0.27 to -0.31), persisting across nonlinear threshold analyses, establish it as a novel biomarker of central adiposity-related skeletal fragility. Unlike conventional indices reflecting mechanical loading benefits (BMI β = 0.008–0.012; WC β = 0.003–0.005; WHtR β = 0.41–0.69), ABSI specifically captures visceral fat-driven metabolic disorder—a critical pathway for osteoporosis risk stratification in normal-weight and obese populations.


  • Open Access

    Emerging trends in the blood spinal-cord barrier: A bibliometric analysis

    by Bo Mm Xu, Dian Mm Zhang, Bowen Yang, Xin Chen, Zhefeng Mm Jin, Xiaokuan Qin, Guoliang Mm Ma, Kai Sun, Liguo Zhu, Xu Wei, et al.

    Background: The blood-spinal cord barrier (BSCB) is a unique protective barrier located between the circulatory system and the central nervous system. BSCB plays a vital role in various diseases. However, there is little systematic research and recording in this field by bibliometrics analysis. We aim to visualize this field through bibliometrics to analyze the hotspots and trends of BSCB and in order to facilitate an understanding of future developments in basic and clinical research. Methods: To conduct a bibliometric study of original publications and their references, the keywords Blood Spinal-Cord Barrier and BSCB are searched and filtered from the Web of Science database (2000–2022), focusing on citations, authors, journals, and countries/regions. Additionally, clustering of the references and co-citation analysis was completed, including a total of 1926 articles and comments. Results: From the results, 193 authors were identified, among which Sharma Hs played a key role. As far as the analysis result of the clustering of the references is concerned, the most common type in cluster analysis is spinal cord injury (SCI) which is a current and developing research field. The keywords are also the specific content under these clusters. The most influential organization is Univ Calif San Francisco, and “Proceedings of The National Academy of Sciences of The United States of America” magazine is the most cited magazine. Conclusion subsections: The research on BSCB is booming focusing mainly on “BSCB in SCI” including “activation,” “pathway,” and “drug delivery” which is also the trend of future research.


  • Open Access

    IL‐6 and Leptin Are Potential Biomarkers for Osteoporotic Fracture Risk Assessment and Prediction of Postmenopausal Women with Low Bone Mass: A Follow‐Up Study Using a Regional Sample Cohort

    by Xu Wang, Yili Zhang, Baoyu Qi, Kai Sun, Chuanrui Sun, Ning Liu, Shengjie Fang, Xu Wei, Yanming Xie, Liguo Zhu

    Osteoporotic fracture, a major complication which is known as the outcome postmenopausal osteoporosis, seriously threatens the health of postmenopausal women. At present, the traditional osteoporotic fracture prediction methods are characterized by inconvenient application and time‐consuming statistical results, while predictive serum biomarkers can make up for this shortcoming. Accurate and advanced risk prediction of osteoporotic fracture is meaningful to early prevention and intervention, effectively avoiding the risk of this disease and the secondary fracture in the surgical treatment. In this study, based on the BEYOND cohort, a 2‐year follow‐up study was conducted after subjects participated to survey if OF occurred. Independent sample t -test and Mann–Whitney U‐test were used to analyze the differences of bone metabolism biomarkers between the OF and non‐OF group. Cox proportional hazard model was used to screen the potential biomarkers might be used to predict OF risk. ROC curves and AUCs were used to analyze the predictive accuracy, and the Delong’s test was used to compare the differences between the AUCs. 15 postmenopausal women with low bone mass and OF were found, and other 60 subjects without OF were matched with 1 : 4, age, and BMI classification as control group. The serum IL‐6 (OR = 1.139, 95%CI = 1.058 − 1.226) and leptin (OR = 0.921, 95%CI = 0.848 − 1.000) were found as OF risk predictive biomarkers for postmenopausal women with low bone mass with high accuracy (IL − 6 = 0.871) (leptin = 0.813) and accuracy enhanced when they were combined (AUC = 0.898). The results of Delong’s test showed that the difference of AUC between leptin and IL‐6&Leptin was meaningful (P = 0.024) but meaningless between IL‐6 and leptin (P = 0.436), IL‐6 and IL‐6&Leptin (P = 0.606). To sum up, IL‐6 and leptin are the predictive biomarkers of OF for postmenopausal women with low bone mass. The IL‐6 can improve the prediction accuracy of leptin (P = 0.024), but not vice versa (P = 0.606). Trial Information. Registered on the Chinese Clinical Trial Registry already. (Registration Number: ChiCTR-SOC-17013090).


  • Open Access

    An evaluation of the effects and safety of Zuogui pill for treating osteoporosis: Current evidence for an ancient Chinese herbal formula

    by Jinyu Li, Kai Sun, Baoyu Qi, Guiyu Feng, Wei Wang, Qi Sun, Chengying Zheng, Xu Wei, Yusong Jia

    The aim of this study is to systematically evaluate existing evidence of the Chinese herbal formula, Zuogui pill (ZGP), for the treatment of osteoporosis. A systematic literature search was performed in six electronic databases. The authors independently extracted data in pairs and evaluated the risk of bias. A total of 221 articles were identified initially, of which 12 relevant studies were enrolled. The primary outcome was fracture incidence and bone mineral density (BMD) at different sites. Bone metabolism markers, clinical symptoms, quality of life, and adverse events or adverse drug reactions (ADRs) were secondary outcomes. The results showed that ZGP, combined with anti‐osteoporosis drugs, significantly increased BMD at the lumbar spine, Ward's area, and total hip. In terms of markers for improved bone metabolism, ZGP plus conventional drugs dramatically improved the levels of alkaline phosphatase, bone Gla protein, bone alkaline phosphatase, and tartrate‐resistant acid phosphatase. Gastrointestinal discomfort, dizziness, and fatigue were found in the combined therapy group. Although the results indicate that ZGP is a potential candidate for osteoporosis, evidence remains insufficient. Further rigorously designed and high‐quality trials with a larger sample size are warranted to verify the current conclusions.